Markets:

Overview

News

Currencies

International

Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.39 -3.23 (-11.69%)

Streaming Delayed Price Updated: 1:13 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022

October 20, 2022

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million

October 13, 2022

-- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September --

From Pacira BioSciences

Via GlobeNewswire

Pacira Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 07, 2022

On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.

Via Investor's Business Daily

Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery ↗

September 21, 2022

Via Benzinga

Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug ↗

September 07, 2022

Via Benzinga

Pacira BioSciences' Return On Capital Employed Overview ↗

August 08, 2022

Via Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗

September 07, 2022

Via Benzinga

Pacira BioSciences: Q2 Earnings Insights ↗

August 03, 2022

Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement.

Via Benzinga

Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022

July 27, 2022

From Pacira BioSciences

Via GlobeNewswire

Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know ↗

June 15, 2022

Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

June 15, 2022

Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday.

Via Benzinga

Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark ↗

June 08, 2022

On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75.

Via Investor's Business Daily

Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82 ↗

June 08, 2022

Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock.

Via Investor's Business Daily

Vertex Pharmaceuticals Receives Composite Rating Upgrade ↗

May 24, 2022

The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals.

Via Investor's Business Daily

Pacira BioSciences's Return on Invested Capital Overview ↗

May 20, 2022

Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters.

Via Benzinga

Gilead Stock Earns Rating Upgrade After Quick Turnaround ↗

May 19, 2022

A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?

Via Investor's Business Daily

Pacira BioSciences: Q1 Earnings Insights ↗

May 04, 2022

Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 28, 2022

Pacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗

April 14, 2022

On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.

Via Investor's Business Daily

28 Biggest Movers From Yesterday ↗

April 12, 2022

Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire...

Via Benzinga

Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 ↗

April 07, 2022

On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.

Via Investor's Business Daily

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

April 06, 2022

On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago.

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

April 04, 2022

Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.

Via Investor's Business Daily

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗

March 25, 2022

Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.

Via Investor's Business Daily

Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗

March 23, 2022

Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.

Via Investor's Business Daily

Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating ↗

March 08, 2022

Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82.

Via Investor's Business Daily

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating ↗

February 07, 2022

The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.